30 results
6-K
EX-99.2
OBSVF
ObsEva SA
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
—with the goal of ultimately offering more individualized treatment options for a broader range of women. I, along with ObsEva’s entire board and leadership team … , look forward to working with Stephanie. We would also like to thank Jacky for his scientific guidance, leadership, vision, and significant
6-K
EX-99.1
OBSVF
ObsEva SA
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
for the Company,” said Brian O’Callaghan, Chief Executive Officer of ObsEva. “Clive has a demonstrated track record of leadership and I am confident he will play … for his leadership and contributions to the Company during his two plus year tenure at ObsEva.”
Clive Bertram joins ObsEva with nearly 30 years
6-K
EX-99.1
OBSVF
ObsEva SA
1 Feb 22
ObsEva Appoints Katja Buhrer as Chief Strategy Officer
6:05am
record managing strategic transactions, partnerships, and investor relations programs strengthens our leadership team as we prepare to transition … to a commercial-stage company. We further look forward to her leadership as we explore new indications, partnerships, and other strategic opportunities
6-K
OBSVF
ObsEva SA
25 Jul 18
Current report (foreign)
8:21am
assignments at PwC Consulting and in different market access leadership roles at Amgen, both in the European headquarters previously based in Luzern … for the company, the addition of Wim’s leadership and knowledge in the commercial field will be invaluable to prepare the company
6-K
EX-99.1
OBSVF
ObsEva SA
6 Apr 20
ObsEva SA Announces New Interim Chief Financial Officer
4:00pm
contributions to the Company and leadership during his tenure at ObsEva. We would also like to thank Fabien for assuming this extended responsibility
6-K/A
EX-99.1
neozvqxtc41 es
19 Jan 21
Current report (foreign) (amended)
6:25am
6-K
EX-99.1
7tzwbtig12ah9x2g h4o
13 Jan 21
Current report (foreign)
4:00pm
6-K
EX-99.3
9g8r9 v97jn0mjnm
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.2
2gp e3dkob
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.2
9ptqnhq74fjmxay596tw
17 Feb 21
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
6:04am
6-K
EX-99.1
hgpz 7kzl7qyzj1
4 Jan 21
ObsEva appoints David Renas as Chief Financial Officer
6:36am
6-K
EX-99.1
58xgrs0av8odfl19 cnw
31 Mar 21
Current report (foreign)
7:15am
6-K
EX-99.1
j9dbkjql9ta7
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
6-K
EX-99.1
q3z0l2
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.1
ygsz8r1
2 May 22
ObsEva Announces Appointment of Dr. Brandi Howard as Chief Clinical Officer
7:00am
6-K
EX-99.1
4wfcf pebwdb1k
7 Apr 22
ObsEva Annual General Meeting 2022
7:01am
6-K
EX-99.1
qr4to3j0yb4l0ty
22 Apr 21
ObsEva Annual General Meeting 2021
6:31am
6-K
EX-99.1
ljn0w u87zar82f
10 Feb 21
ObsEva Provides Business Outlook for 2021
6:10am
6-K
EX-99.1
1wvqa5dpien9k5usd
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
6-K
3li32wue2 ur
15 Jan 20
Current report (foreign)
8:35pm